Teva Pharmaceuticals stock surges 12% as branded drug sales outperform

Core Insights - Teva Pharmaceutical Industries Ltd. stock increased by 12% following the release of stronger-than-expected third-quarter results [1] - The growth was primarily driven by robust performance in its branded drug portfolio [1] Financial Performance - The third-quarter results exceeded market expectations, indicating a positive trend in the company's financial health [1] - The specific figures related to revenue or profit were not disclosed in the provided content, but the overall performance was highlighted as strong [1]